Available Strengths

• Doxorubicin Hydrochloride Liposome (Pegylated) Injection: 2 mg/mL

Presentation sizes may vary according to manufacturer specifications and country registration.

Frequently Asked Questions

1. What is Doxorubicin Hydrochloride Liposome (Pegylated) Injection used for?

It is used in the treatment of selected cancers such as ovarian cancer, metastatic breast cancer, AIDS-related Kaposi sarcoma, and multiple myeloma in combination with other medicines as determined by an oncologist.

2. How is the liposomal formulation different?

The pegylated liposomal formulation is designed to improve drug delivery and prolong circulation time, helping deliver the medicine differently from conventional doxorubicin formulations.

3. Can this medicine be exported internationally?

Yes. Licensed hospitals, oncology centers, government procurement agencies, pharmaceutical distributors, and registered importers may source this product through authorized pharmaceutical exporters.

4. What documentation is generally available?

Depending on manufacturer availability, documentation may include COA, batch COA, product specifications, manufacturing license, GMP certificate, commercial invoice, packing list, and certificate of origin.

5. Is this medicine suitable for self-administration?

No. It must be administered only by trained healthcare professionals in hospitals or specialized oncology treatment centers.

Demand for Doxorubicin Hydrochloride Liposome (Pegylated) Injection 2 mg/mL continues to grow as healthcare providers increasingly utilize advanced liposomal formulations in oncology care. International hospitals, cancer institutes, and pharmaceutical importers seek reliable suppliers capable of providing GMP-manufactured products, regulatory documentation, and dependable global export services.